

# 1 **Dengue severity by serotype in 19 years of pediatric clinical studies in Nicaragua**

2

3 Federico Narvaez<sup>1,2</sup>, Carlos Montenegro<sup>2</sup>, Jose Guillermo Juarez<sup>2</sup>, Jose Victor Zambrana<sup>2,3</sup>, Karla  
4 Gonzalez<sup>2,4</sup>, Sonia Arguello<sup>2</sup>, Fanny Barrios<sup>1,2</sup>, Sergio Ojeda<sup>2</sup>, Miguel Plazaola<sup>2</sup>, Nery Sanchez<sup>2</sup>,  
5 Daniel Camprubi<sup>5a</sup>, Guillermina Kuan<sup>6</sup>, Gabriela Paz Bailey<sup>5</sup>, Eva Harris<sup>7</sup>, Angel Balmaseda<sup>2,4</sup>

6

7 <sup>1</sup> Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud,  
8 Managua, Nicaragua

9 <sup>2</sup>Sustainable Sciences Institute, Managua, Nicaragua

10 <sup>3</sup>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,  
11 Michigan, USA

12 <sup>4</sup>Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de  
13 Salud, Managua, Nicaragua

14 <sup>5</sup>Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic  
15 Infectious Diseases, San Juan, Puerto Rico

16 <sup>6</sup>Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

17 <sup>7</sup>Division of Infectious Diseases and Vaccinology, University of California, Berkeley, Berkeley, CA

18

19 <sup>a</sup>Current affiliation: ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain

20 Section: Vector-borne Diseases or Global Health and Neglected Tropical Diseases

21

22 Corresponding author: Angel Balmaseda, [abalmaseda40@gmail.com](mailto:abalmaseda40@gmail.com)

23 **Summary:** We analyzed dengue virus (DENV) disease severity stratified by serotype and immune  
24 status over 19 years of two pediatric studies in Nicaragua. DENV2 and DENV3 caused the most  
25 severity – primarily secondary DENV2 cases and both primary and secondary DENV3 cases.

26

27 **Keywords:** dengue, serotype, disease severity, immune status, pediatric

28 **Abstract**

29 **Background.** Dengue virus, a major global health threat, consists of four serotypes (DENV1-4)  
30 that cause a range of clinical manifestations from mild to severe and potentially fatal disease.

31 **Methods.** This study, based on 19 years of data from the Pediatric Dengue Cohort Study and  
32 Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the influence of  
33 serotype and immune status on dengue severity. Study participants 6 months to 17 years old  
34 were followed during their hospital stay or as ambulatory patients, with dengue cases  
35 confirmed by molecular, serological, and/or virological methods.

36 **Results.** We enrolled a total of 14071 participants, of whom 2954 (21%) were positive for DENV  
37 infection. Of 2425 cases with serotype result by RT-PCR, 541 corresponded to DENV1, 996 to  
38 DENV2, 718 to DENV3 and 170 to DENV4. Severe disease was more prevalent among  
39 secondary DENV2 and DENV4 cases, while similar disease severity was observed in both  
40 primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health  
41 Organization (WHO) severity classification, both DENV2 and DENV3 had a higher proportion of  
42 severe disease compared to other serotypes, whereas DENV3 had the greatest percentage of  
43 severity under the WHO-2009 classification. DENV2 was associated with pleural effusion and  
44 low platelet count, while DENV3 correlated with both hypotensive and compensated shock.

45 **Conclusions.** These findings emphasize the critical need for a dengue vaccine with balanced  
46 efficacy against all four serotypes, particularly as existing vaccines show variable efficacy by  
47 serotype and immune status, posing challenges for comprehensive protection, particularly in  
48 dengue-naïve individuals.

49

## 50 Introduction

51 The four serotypes of dengue virus (DENV1-4), a mosquito-borne *Flavivirus*, affect tens of  
52 millions of people worldwide [1]. In recent decades, dengue epidemics have consistently  
53 increased in tropical and subtropical regions of the world, with vector control as the principal  
54 means of prevention due to the lack of an effective, broadly used vaccine. Dengue viruses  
55 cause a range of clinical manifestations, from mild to severe and potentially fatal [2].  
56 Understanding the contribution of serotype and immune status (primary versus secondary  
57 DENV infection) to clinical spectrum and severe disease is important for developing effective  
58 prevention and control strategies, particularly when introducing new vaccines with differential  
59 efficacy [3,4].

60

61 Developing a dengue vaccine has been challenging, primarily because it needs to provide  
62 protection against all four DENV serotypes, as imbalanced protection may result in antibody-  
63 dependent enhancement (ADE) of infection and disease [5,6]. The two approved dengue  
64 vaccines vary in efficacy by serotype and immune status. Specifically, Dengvaxia shows low  
65 efficacy for DENV2 and results in increased risk of hospitalization when administered to DENV-  
66 naïve recipients [7]; QDenga has no efficacy against DENV3 in dengue-naïve children and  
67 unknown efficacy against DENV4 [8]. Importantly, both DENV2 and DENV3 have been  
68 associated with the greatest clinical severity [9–13]. Previous studies in our hospital cohort in  
69 Nicaragua also showed that DENV2 had a higher frequency of shock and internal hemorrhage  
70 when compared to DENV1 [14]. However, a comprehensive understanding of how dengue

71 severity varies by serotype and immune status remains limited, especially in Latin America  
72 compared to other regions like Southeast Asia [10–13].

73  
74 For the past 19 years, we have conducted studies on the diagnosis, classification, and clinical  
75 management of dengue in Managua, Nicaragua [14–19]. This article describes the clinical  
76 features and severe outcomes of dengue cases stratified by serotype and immune status in  
77 almost 3000 patients presenting to our study health center or directly to our study hospital and  
78 followed over the entire course of illness. Our results add to the clinical knowledge base of  
79 dengue and can inform public health policies regarding implementation of novel vaccines for  
80 disease control.

81

## 82 **Methods**

83 **Study design.** We leverage two ongoing studies in Managua: the Pediatric Dengue Cohort  
84 Study (PDCS; 2004 to present) and the Pediatric Dengue Hospital-based study (PDHS; 2005 to  
85 present). The PDCS is the longest ongoing prospective dengue cohort study, currently in its 20<sup>th</sup>  
86 year, following ~4,000 children aged 2-17 years old (y/o) in a community-based context, with  
87 enhanced passive surveillance at the Health Center Sócrates Flores Vivas (HCSFV) in District 2 of  
88 Managua [20]. To maintain the PDCS, 200-300 new 2-y/o children are enrolled every year,  
89 along with an additional ~200 children 3-8 y/o to compensate for loss to follow-up [20]. The  
90 PDHS is a clinical study that enrolls patients every year during the dengue season at the  
91 Hospital Infantil Manuel de Jesus Rivera (HIMJR), Nicaragua's national pediatric reference  
92 hospital. The PDHS enrolls children from 6 months to 14 y/o with symptoms and signs

93 suggestive of an arbovirus infection (WHO 1997) either in the emergency room or in the  
94 infectology unit of HIMJR [16] Children in the PDCS who require hospitalization are referred to  
95 the HIMJR, including patients 15-17 y/o. All participants were followed for their entire course of  
96 illness. Both the HCSFV and the HIMJR provide free health care services. Here, we present  
97 information from patients enrolled in both studies from September 2004 to February 2023.

98 **Classification of dengue disease severity.** Dengue disease severity is defined by the World  
99 Health Organization (WHO) guidelines of 1997 (Dengue Fever [DF], Dengue Hemorrhagic Fever  
100 [DHF], Dengue Shock Syndrome [DSS]) [21] and 2009 (Dengue without Warning Signs [DwoWS],  
101 Dengue with Warning Signs [DwWS] and Severe Dengue [SD]) [2]. See Supplementary Table for  
102 more details. Here, we defined severe dengue disease as DHF/DSS (1997) or SD (2009).

103  
104 **Laboratory methods and dengue diagnostics.** Cell blood counts and blood chemistry tests  
105 were conducted using a Cell/Dyn Rubi (Abbot) and Biosystems BA 400 (Biosystems) automated  
106 system, respectively, and the trend over time in each patient's platelet and hematocrit values  
107 was reviewed. Dengue cases were confirmed by: 1) RT-PCR/viral isolation in acute samples  
108 and/or 2) seroconversion by DENV IgM MAC-ELISA and/or a seroconversion or  $\geq 4$ -fold increase  
109 in total DENV antibody titers as measured by the Inhibition ELISA (iELISA) in paired acute and  
110 convalescent sera [22,23]. Viral RNA was initially detected using a nested RT-PCR and then  
111 using a multiplex Zika-Chikungunya-Dengue (ZCD) real-time RT-PCR [24–26]. DENV-positive  
112 samples were further analyzed to identify the infecting serotype using a multiplex DENV rRT-  
113 PCR [27]. Immune status was determined using iELISA in early convalescent samples;  $< 2,560$   
114 was considered primary infection and  $\geq 2,560$  was considered secondary [15,22].

115

116 **Statistical methods.** Descriptive statistics were used to summarize demographic and dengue  
117 case data from the PDCS and PDHS, yielding participant counts, serotype distribution, and  
118 incidence data (see Supplementary Figures for a breakdown of all results by study). Incidence  
119 and distribution of infections by serotype and year were calculated. In addition, we analyzed  
120 severity by serotype using both the 1997 and 2009 WHO classifications, reporting the  
121 distribution of primary and secondary DENV infections and the severity classifications by each  
122 serotype in raw numbers and percentages. To analyze severity based on the 1997 and 2009  
123 WHO dengue classifications by serotype and immune status, we used marginal effects from  
124 multivariate logistic regressions, producing predictive percentages of severe cases by serotype  
125 and immune status and applying an interaction term by serotype and immune status,  
126 controlling for age and sex.

127

128 We implemented separate logistic regression models adjusting by immune status to calculate  
129 the odds ratios of each symptom and sign by serotype, using DENV1 as the reference value.  
130 The signs and symptoms comprised a range of clinical indicators such as hypotensive shock,  
131 poor capillary refill, pleural effusion, shock, hemoconcentration, low platelet counts, mucosal  
132 bleeding, ICU admission, inotropic drug usage, abdominal pain, vomiting, rash, headache, and  
133 myalgia. All analyses were performed in R version 4.2.2 (R core Team). All the analysis and  
134 figures were also stratified by study (PDCS and PDHS), these are shown in Supplementary  
135 Figures 1-8.

136

137

138

139 **Ethics**

140 The PDCS and PDHS are approved by the Institutional Review Boards of the Nicaraguan Ministry  
141 of Health (Protocol #CIRE-09/03/07-008.Ver24, CIRE-01/10/06-13.ver8) and the UC Berkeley  
142 Committee for the Protection of Human Subjects (Protocols 2010-09-2245, 2010-06-1649).  
143 Informed consent was obtained from all participants, parents, or legal guardians before  
144 enrollment; verbal assent was obtained from children 6-11 y/o and written assent from  
145 children  $\geq 12$  y/o.

146

147 **Results**

148 **Demographic data and dengue cases.** This study includes 14071 participants, of whom 2954  
149 were positive for DENV infection. Yearly enrollment (PDHS) or community-based dengue cases  
150 (PDCS) varied depending on the epidemic season, with a maximum of 1751 children in 2019, a  
151 minimum of 37 children in 2004, and an average of 101 (standard deviation = 82) children per  
152 year combining both studies. Of the 2954 dengue cases, 2425 were DENV-positive by RT-PCR,  
153 with 541 DENV1, 996 DENV2, 718 DENV3, and 170 DENV4 (Table 1). Children were distributed  
154 almost evenly by sex, with 1207 (50%) females, and the average age of disease onset was 9  
155 years in both studies (PDCS= 9.43 y/o, PDHS= 8.94 y/o) (Table 1). Children were followed  
156 throughout the course of disease and were managed as inpatients (mean hospitalization = 4.3  
157 days) or outpatients (mean follow-up = 2.2 days) depending on disease severity. Of the 1132



158 PDCS DENV-positive participants, 397 (35%) required hospitalization and were transferred to  
159 the study hospital.

160  
161 **DENV serotype and immune status.** Over the 19 years of the studies, we observed varying  
162 patterns of circulating DENV serotypes. DENV2 and DENV3 were the most common serotypes,  
163 with predominantly secondary infections for DENV2 and similar numbers of primary and  
164 secondary infections for DENV3 (Figure 1). Similar trends were observed in the PDCS and PDHS  
165 (Supplementary Figure 1). Interestingly, after 5 years of only DENV2 detection followed by 2  
166 years of COVID-19 travel restrictions, in 2022, we detected epidemic levels of DENV4 for the  
167 first time and simultaneous circulation of all four serotypes. We observed 852 primary  
168 infections and 1573 secondary infections, with primary infections being most frequent in the  
169 ages of 6-10 years and secondary infections most prevalent in ages 11-17 years, with an almost  
170 equal distribution of sex (Table 2).

171  
172 **Dengue severity by immune status and serotype.** The clinical spectrum caused by each  
173 serotype was analyzed based on 1997 and 2009 WHO definitions [2,21]. Using the 1997  
174 classification, 1980 (80%) patients were DF and 411 (20%) were DHF/DSS (Table 3). Here,  
175 severity was defined as DHF/DSS. Using WHO-2009, 1403 (59%) patients were classified as  
176 DwWS and 408 (30%) with SD; therefore, severity was defined as SD (Table 3). Evaluating  
177 immune status, we observed that secondary cases were much more prevalent in severe disease  
178 caused by DENV2 infections (WHO-1997: 212 [92%] and WHO-2009: 110 [89%]) and DENV4  
179 infections (WHO-1997: 4 [100%] and WHO-2009: 7 [100%]), while for DENV1 (WHO-1997: 26

180 [63%] secondary and WHO-2009: 48 [57%] secondary) and DENV3 (WHO-1997: 85 [61%]  
181 secondary and WHO-2009: 95 [49%] secondary), disease severity was observed in both primary  
182 and secondary infections (Table 3, Figure 2). Similar trends were observed in the PDCS and  
183 PDHS (Supplementary Figure 2). Thus, DENV3 was associated with the greatest severity in both  
184 primary and secondary infections according to both 1997 and 2009 WHO classifications, while  
185 DENV2 was most associated with DHF/DSS in secondary cases (see model-derived estimates  
186 compared to DENV1 in Figure 3 and Supplementary Figure 3).

187  
188 **Clinical signs and symptoms by serotype.** Compared to DENV1, patients with DENV2 had  
189 greater odds of ICU admission (Odds Ratio [OR] 2.71, 95% confidence interval [CI]: 1.43-5.62),  
190 hemoconcentration (OR=4.80, 2.06-14.04), low platelet count (OR=1.64, 1.27-2.14 for <100,000  
191 and OR=2.91, 1.92-4.56 for <50,000), pleural effusion (OR=2.84, 2.1-3.88), and mucosal  
192 bleeding (OR=1.47, 1.01-2.18), the last only in secondary infections (Figure 4 and  
193 Supplementary Figure 4). We also observed a higher risk for rash (OR=1.87, 1.49-2.34) and  
194 fewer cases reporting headache (OR= 0.47, 0.37-0.59) and myalgia (OR=0.69, 0.54-0.88)  
195 compared to DENV1 (Figure 5). For DENV3, we observed an association with general symptoms  
196 such as rash (OR=3.11, 2.43-4.00) and myalgia (OR=1.58, 1.24-2.01) and alarm signs such as  
197 abdominal pain (OR=2.96, 2.28-3.87) and mucosal bleeding (OR=1.91, 1.42-2.58) (Figure 5). In  
198 terms of severity, DENV3 was correlated with pleural effusion (OR=2.54, 1.86-3.50), poor  
199 capillary refill (OR=2.06, 1.52-2.79), compensated shock (OR=2.30, 1.68-3.19), and hypotensive  
200 shock (OR=2.21, 1.46-3.42) (Figure 4). See Supplementary Figures 3-8 stratified by immune  
201 status and study.

202  
203 Severe dengue cases, defined by the WHO-2009 criteria, were primarily characterized by shock.  
204 The WHO-2009 definition encompasses both compensated and hypotensive shock, unlike the  
205 WHO-1997 DSS definition, which includes only cases with hypotensive shock. Table 4 depicts  
206 patients identified upon admission with either compensated or hypotensive shock and those  
207 progressing from compensated to hypotensive shock, regardless of medical intervention.  
208 Notably, the severity of DENV1 is characterized by compensated shock, with only 12 (14%) of  
209 patients progressing from compensated to hypotensive shock, in contrast to DENV2 and DENV3,  
210 where more cases presented with hypotensive shock (30 [26%] and 24 [13%], respectively) or  
211 progressed from compensated to hypotensive shock (41 [35%] or 69 [37%], respectively).  
212 Further, other symptoms indicative of plasma leakage, such as pleural effusion and ascites,  
213 were higher in DENV2 (32% and 40%, respectively) and DENV3 (26% and 24%, respectively)  
214 compared to DENV1 (12% and 14%, respectively) (Figures 4 and 5 and Supplementary Figures 3-  
215 8 stratified by immune status and study). ICU admission was highest in DENV2 infections (11%)  
216 and lower in DENV1 (4%) and DENV3 (6%) cases. Laboratory abnormalities such as  
217 hemoconcentration and thrombocytopenia were more common in DENV2 (6% and 43%,  
218 respectively) and lower in DENV1 (1% and 25%) and DENV3 (1% and 29%).

219

## 220 **Discussion**

221 Dengue virus continues to expand globally, with multiple serotypes co-circulating that cause a  
222 wide range of clinical outcomes and can be potentially fatal. To evaluate how disease severity  
223 is modulated by immune status and DENV serotype, we leveraged two complementary long-

224 term studies in Nicaragua, including an integrated follow-up system from primary health center  
225 to hospital, based on 19 years of data. We used both the 1997 and 2009 WHO severity  
226 classification schemes, revealing important distinctions. Overall, we found that DENV2 and  
227 DENV3 caused the highest percent of DHF/DSS, and DENV3 caused the highest percent of SD, as  
228 well as the greatest number of severe clinical manifestations. This is consistent with previous  
229 publications [10–13,28,29] and of concern given that currently approved vaccines have poor  
230 efficacy against DENV2 for Dengvaxia and DENV3 for the Takeda vaccine in dengue-naïve  
231 recipients [7,8].

232  
233 When analyzing immune status by serotype, we found that secondary cases predominated for  
234 DENV2 and DENV4, whereas more similar numbers of primary and secondary cases were  
235 observed for DENV1 and DENV3, supported by the literature [14,29–31]. Even in younger age  
236 groups, DENV2 and DENV4 showed a higher percentage of secondary cases, suggesting that  
237 primary cases infected by these serotypes were asymptomatic, consistent with previous reports  
238 [12,28,29,32]. Likewise, severe disease occurred much more often in secondary DENV2 and  
239 DENV4 cases, in contrast to DENV1 and DENV3 severe cases, which were more evenly  
240 distributed among primary and secondary cases, as reported elsewhere as well [13,28,30].

241  
242 We analyzed the clinical spectrum of dengue considering the two distinct WHO severity  
243 classifications of 1997 and 2009. The 1997 definition is more focused on the pathophysiology  
244 of vascular leak leading to shock, while the 2009 definition aims for real-time identification of  
245 clinical disorders to enable timely management. The clinical spectrum of dengue using the

246 WHO-1997 definition revealed that most dengue cases evolved as DF, regardless of the  
247 serotype involved, with approximately 20% being classified as DHF/DSS. In contrast, using the  
248 2009 classification, only 10% of cases evolved as DwoWS, with the majority as DwWS and 30%  
249 classified as SD. Approximately two-thirds of the patients classified as severe (DHF/DSS, WHO-  
250 1997) were classified as DwWS (WHO-2009). All exhibited a clinical picture characterized by  
251 plasma leakage and thrombocytopenia that did not progress to shock or respiratory distress.  
252 Other markers of severity such as plasma leakage that may not have progressed to shock and  
253 ICU admission were more common among DENV2 cases, underscoring the importance of this  
254 serotype.

255  
256 Breaking this down by serotype and immune status, secondary cases showed a higher  
257 proportion of WHO-1997 severe disease (DHF/DSS), especially in the case of DENV2 for DSS,  
258 while DENV3 had a high proportion of DHF/DSS in secondary cases as well as primary cases.  
259 Using the WHO-2009 classification, the serotype that exhibited the highest proportion of SD  
260 cases was DENV3 for both primary and secondary infections. However, overall, DENV2 was  
261 associated with severity using the 1997 classification, whereas DENV3 exhibited more severe  
262 cases according to both 1997 and 2009 definitions. It is important to note that the WHO-1997  
263 DSS definition includes only cases with hypotensive shock, unlike the WHO-2009 SD definition,  
264 which encompasses both compensated and hypotensive shock.

265  
266 With respect to clinical signs and symptoms, severe thrombocytopenia (<50,000 platelets) was  
267 five times more prevalent in DENV2 than in DENV3 cases. On the other hand, of the WHO-2009

268 SD cases, two-thirds were not classified as severe by WHO-1997, because they failed to meet  
269 the full criteria for DHF/DSS. These were predominantly DENV3 cases (50%) followed by DENV1  
270 and DENV2, almost entirely characterized by some form of shock without thrombocytopenia or  
271 hemorrhagic manifestations. Interestingly, most severe cases of DENV1 did not progress to  
272 hypotensive shock, maintaining only hemodynamic alterations such as poor capillary refill  
273 without advancing to hypotension and/or decreased pulse pressure. This is why DENV1  
274 appears to be more severe than DENV2 when applying the 2009 classification. The severity of  
275 both DENV2 and DENV3 is characterized by signs of plasma leakage, resulting in ascites and  
276 pleural effusion. However, in comparison with DENV1, DENV3 is significantly associated with  
277 hemodynamic alterations leading to shock, either in its initial, compensated stage or during the  
278 hypotensive phase. Surprisingly, DENV2 did not have this association with shock, whether  
279 compensated or hypotensive, when compared to DENV1. This discrepancy may be attributed to  
280 a marked difference in the severity of DENV2 when analyzing immune status, where primary  
281 cases evolve favorably. Previous reports have also identified that DENV2 (WHO-1997) and  
282 DENV3 (WHO-1997 and WHO-2009) account for the greatest dengue severity [10,13,28,33].

283  
284 One of our main strengths is the longitudinal nature of the study, with a single protocol in place  
285 for over almost two decades with consistency of clinical care and data collection. Another is the  
286 large number (almost 3000) of laboratory-confirmed pediatric dengue cases. Finally, we  
287 analyzed community-based and hospital-based cases, as well as those who progressed from the  
288 health center to the hospital – made possible by over a decade of careful work by our  
289 physicians harmonizing clinical variables between the two sites and a dedicated team of

290 programmers and data managers creating our customized informatics system and algorithm  
291 pipelines.

292  
293 One limitation of our study was the low circulation of DENV4, which prevented us from  
294 comprehensively analyzing the clinical signs and symptoms of severity in this serotype.  
295 Additionally, at the time of this analysis, one lineage of each serotype had circulated in  
296 Managua during the study period. We plan to expand this analysis following the introduction of  
297 new lineages of all the serotypes in 2022 (C. Cerpas, A. Balmaseda, in revision).

298  
299 Overall, our study reveals that DENV2 and DENV3 consistently lead to the highest severity in  
300 dengue cases. DENV2 primarily impacts secondary cases, while DENV3 induces severity  
301 regardless of immune status. These findings highlight the complex interplay between dengue  
302 serotypes, disease severity classifications, and immune status. Furthermore, our findings  
303 underscore the need for a vaccine that offers consistent efficacy against all four serotypes.

304

### 305 **Notes**

306 ***Authors contributions.*** FN, JGJ, GPB, EH, and AB contributed to the conceptualization of the  
307 study. FN, GK, and AB supervised the clinical studies. FN, FB, SO, MP, and NS conducted the  
308 studies. KG performed laboratory assays. CM and SA curated the data. JVZ, JGJ, DC and AB  
309 analyzed the data. JGJ, JVZ, DC, EH, and AB generated the initial figures and tables. FN, JGJ,  
310 EH, and AB wrote the initial manuscript draft, and DC and GPB edited the manuscript. All  
311 authors reviewed the manuscript for scientific content.

312

313 **Acknowledgments.** We are grateful to Cesar Narvaez for his contribution to data management  
314 for the Pediatric Dengue Hospital-based Study. We thank both past and current team members  
315 of the studies, based at the Hospital Infantil Manuel de Jesús Rivera, Sócrates Flores Vivas  
316 Health Center, the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y  
317 Referencia, and the Sustainable Sciences Institute in Nicaragua for their commitment and  
318 exceptional work. We are deeply grateful to the participants of the Pediatric Dengue Cohort  
319 Study and Pediatric Dengue Hospital-based Study and their families.

320  
321 **Financial support.** This work was supported by the National Institute for Allergy and Infectious  
322 Diseases (NIAID) of the National Institutes of Health (NIH) grant numbers P01 AI106695 (EH)  
323 and R01 AI099631 (AB). The studies were supported by P01 AI106695 (EH), U01 AI153416 (EH),  
324 U19 AI118610 (EH), R01 AI099631 (AB), U54 AI65359 (Barbour; subcontract AB), and BAA-  
325 NIAID-DAIT-NIHA12009061 (Loeb; subcontract AB) from NIAID/NIH, and the the Pediatric  
326 Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from the Bill and Melinda  
327 Gates Foundation.

328  
329 **Potential conflicts of interest.** The authors declare no conflicts of interest.

330  
331 **Data and materials availability.** After securing approval from the UC Berkeley Committee for  
332 the Protection of Human Subjects, individual data for figure reproduction can be shared with  
333 external researchers. For data access arrangements, please contact E.H. at  
334 eharris@berkeley.edu or the CPHS at ophs@berkeley.edu. Standard data transfer agreements



335 govern all data used in this study. The associated code is available at the following link:

336 [https://github.com/jgjuarez/Narvaez\\_Dengue\\_Clinical\\_Severity](https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity).

337

338 ***Disclaimer.*** The findings and conclusions in this report are those of the author(s) and do not

339 necessarily represent the views of the Centers for Disease Control and Prevention.

## 340 References

- 341 1. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global  
342 variation in dengue transmission intensity. *Sci Transl Med* **2020**; 12:eaax4144.
- 343 2. WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition.  
344 **2009**.
- 345 3. de Silva A. Safety of Dengue Vaccine? *Clin Infect Dis* **2023**; 76:371–372.
- 346 4. Biswal S, Patel SS, Rauscher M. Safety of Dengue Vaccine? *Clin Infect Dis* **2022**; 76:771–772.
- 347 5. Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.  
348 *Microbiol Spectrum* **2014**; 2:10.1128/microbiolspec.aid-0022–2014.
- 349 6. de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should  
350 We Be Concerned about Enhanced Disease after Vaccination? *Cold Spring Harb Perspect*  
351 *Biol* **2018**; 10:a029371.
- 352 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine  
353 Safety and Efficacy. *N Engl J Med* **2018**; 379:327–340.
- 354 8. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda’s Dengue  
355 Vaccine Candidate (TAK-003). *Clin Infect Dis* **2022**; 75:107–117.
- 356 9. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue Viremia Titer, Antibody Response  
357 Pattern, and Virus Serotype Correlate with Disease Severity. *J Infect Dis* **2000**; 181:2–9.
- 358 10. Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of  
359 dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to  
360 2006. *PLoS Negl Trop Dis* **2010**; 4:e617.
- 361 11. Suppiah J, Ching S-M, Amin-Nordin S, et al. Clinical manifestations of dengue in relation to  
362 dengue serotype and genotype in Malaysia: A retrospective observational study. *PLoS Negl*  
363 *Trop Dis* **2018**; 12:e0006817.
- 364 12. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de  
365 Cuba, 1997. *Am J Epidemiol* **2000**; 152:804.
- 366 13. Lovera D, Martínez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical  
367 manifestations of primary and secondary dengue in Paraguay and its relation to virus  
368 serotype. *J Infect Dev Ctries* **2019**; 13:1127–1134.
- 369 14. Balmaseda A, Hammond S, Pérez L, et al. Serotype-specific differences in clinical  
370 manifestations of dengue. *Am J Trop Med Hyg* **2006**; 74:449–456.

- 371 15. Gutiérrez G, Gresh L, Pérez MÁ, et al. Evaluation of the Diagnostic Utility of the Traditional  
372 and Revised WHO Dengue Case Definitions. *PLoS Negl Trop Dis* **2013**; 7:e2385.
- 373 16. Narvaez F, Gutierrez G, Pérez MA, et al. Evaluation of the Traditional and Revised WHO  
374 Classifications of Dengue Disease Severity. *PLoS Negl Trop Dis* **2011**; 5:e1397.
- 375 17. Hammond SN, Balmaseda A, Pérez L, et al. Differences in dengue severity in infants,  
376 children, and adults in a 3-year hospital-based study in NICARAGUA. *Am J Trop Med Hyg*  
377 **2005**; 73:1063–1070.
- 378 18. Rocha C, Silva S, Gordon A, et al. Improvement in hospital indicators after changes in  
379 dengue case management in Nicaragua. *Am J Trop Med Hyg* **2009**; 81:287–292.
- 380 19. Biswas HH, Ortega O, Gordon A, et al. Early Clinical Features of Dengue Virus Infection in  
381 Nicaraguan Children: A Longitudinal Analysis. *PLoS Negl Trop Dis* **2012**; 6:e1562.
- 382 20. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study  
383 Design, Methods, Use of Information Technology, and Extension to Other Infectious  
384 Diseases. *Am J Epidemiol* **2009**; 170:120–129.
- 385 21. WHO, editor. *Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control*.  
386 2nd ed. Geneva: World Health Organization, 1997.
- 387 22. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe  
388 dengue disease in humans. *Science* **2017**; 358:929–932.
- 389 23. Balmaseda A, Sandoval E, Pérez L, Gutiérrez CM, Harris E. Application of molecular typing  
390 techniques in the 1998 dengue epidemic in Nicaragua. *Am J Trop Med Hyg* **1999**; 61:893–  
391 897.
- 392 24. Waggoner JJ, Ballesteros G, Gresh L, et al. Clinical evaluation of a single-reaction real-time  
393 RT-PCR for pan-dengue and chikungunya virus detection. *J Clin Virol* **2016**; 78:57–61.
- 394 25. Harris E, Roberts TG, Smith L, et al. Typing of Dengue Viruses in Clinical Specimens and  
395 Mosquitoes by Single-Tube Multiplex Reverse Transcriptase PCR. *J Clin Microbiol* **1998**;  
396 36:2634–2639.
- 397 26. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of  
398 dengue viruses from clinical samples by using reverse transcriptase-polymerase chain  
399 reaction. *J Clin Microbiol* **1992**; 30:545–551.
- 400 27. Waggoner JJ, Abeynayake J, Sahoo MK, et al. Single-Reaction, Multiplex, Real-Time RT-PCR  
401 for the Detection, Quantitation, and Serotyping of Dengue Viruses. *PLoS Negl Trop Dis*  
402 **2013**; 7:e2116.

- 403 28. Soo K-M, Khalid B, Ching SM, Chee H-Y. Meta-Analysis of Dengue Severity during Infection  
404 by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS ONE **2016**;  
405 11.
- 406 29. Balmaseda A, Standish K, Mercado JC, et al. Trends in Patterns of Dengue Transmission  
407 over 4 Years in a Pediatric Cohort Study in Nicaragua. J Infect Dis **2010**; 201:5–14.
- 408 30. Harris E, Videa E, Pérez L, et al. Clinical, epidemiologic, and virologic features of dengue in  
409 the 1998 epidemic in Nicaragua. Am J Trop Med Hyg **2000**; 63:5–11.
- 410 31. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, et al. Sequential dengue virus infections  
411 detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public  
412 Health **2015**; 15:250.
- 413 32. Yung C-F, Lee K-S, Thein T-L, et al. Dengue Serotype-Specific Differences in Clinical  
414 Manifestation, Laboratory Parameters and Risk of Severe Disease in Adults, Singapore. Am  
415 J Trop Med Hyg **2015**; 92:999–1005.
- 416 33. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic Studies on Dengue in Santiago de  
417 Cuba, 1997. Am J Epidemiol **2000**; 152:793–799.
- 418

419 **Tables**

420

421

422 **Table 1. Study population: Demographic information, DENV serotype, and health facility,**

423 **PDCS and PDHS, Managua, Nicaragua, 2004-2023.**

	<b>Cohort HC* only (n= 735)</b>	<b>Hospital (n= 1,284)</b>	<b>Transferred from cohort HC to Hospital (n=397)</b>
<b>Age</b>	9.43 (SD= 3.57)	8.94 (SD= 3.79)	10.48 (SD= 3.38)
<b>&lt; 1</b>	0 (0%)	29 (2.3%)	0 (0%)
<b>1-5</b>	118 (16%)	232 (18%)	38 (9.6%)
<b>6-10</b>	333 (45%)	499 (39%)	144 (36%)
<b>11-14</b>	236 (32%)	520 (41%)	172 (43%)
<b>15-17</b>	59 (7.9%)	3 (0.2%)	42 (11%)
<b>Sex</b>			
<b>Female</b>	388 (51%)	619 (48%)	200 (50%)
<b>Serotype</b>			
<b>DENV1</b>	193 (26%)	266 (21%)	84 (21%)
<b>DENV2</b>	310 (42%)	540 (42%)	146 (37%)
<b>DENV3</b>	159 (21%)	445 (35%)	114 (29%)
<b>DENV4</b>	84 (11%)	32 (2.5%)	54 (14%)

424 \*Health Center

425

426 **Table 2. Age distribution of dengue cases by DENV serotype and immune status, PDCS and**  
 427 **PDHS, Managua, Nicaragua, 2004-2023.**

Serotypes	DENV1		DENV2		DENV3		DENV4	
Age group	primary	secondary	primary	secondary	primary	secondary	primary	secondary
< 1	6 (2.1%)	0 (0%)	8 (4.7%)	1 (0.1%)	12 (3.2%)	2 (0.6%)	0 (0%)	0 (0%)
1-5	55 (20%)	11 (4.2%)	45 (26%)	93 (11%)	137 (37%)	39 (11%)	5 (18%)	3 (2.1%)
6-10	120 (43%)	99 (38%)	79 (46%)	301 (37%)	165 (45%)	165 (47%)	10 (36%)	37 (26%)
11-14	97 (34%)	135 (52%)	36 (21%)	393 (48%)	53 (14%)	129 (37%)	7 (25%)	78 (55%)
15-17	4 (1.4%)	14 (5.4%)	4 (2.3%)	36 (4.4%)	3 (0.8%)	13 (3.7%)	6 (21%)	24 (17%)
<b>Sex</b>								
F	135 (48%)	122 (47%)	89 (52%)	397 (48%)	187 (51%)	181 (52%)	19 (68%)	77 (54%)
M	147 (52%)	137 (53%)	83 (48%)	427 (52%)	183 (49%)	167 (48%)	9 (32%)	65 (46%)

428

429 **Table 3. Dengue severity by serotype and immune status using the WHO 1997 and 2009**  
 430 **classifications, Pediatric Dengue Cohort Study and Hospital-based study, Managua, Nicaragua,**  
 431 **2004-2023.**

Serotypes	DENV1		DENV2		DENV3		DENV4	
	primary	secondary	primary	secondary	primary	secondary	primary	secondary
<b>WHO-1997</b>								
<b>DF</b>	256 (94%)	228 (90%)	154 (92%)	609 (74%)	315 (86%)	260 (75%)	26 (100%)	132 (97%)
<b>DHF</b>	12 (4.4%)	22 (8.7%)	12 (7.1%)	167 (20%)	41 (11%)	72 (21%)	0 (0%)	3 (2.2%)
<b>DSS</b>	3 (1.1%)	4 (1.6%)	2 (1.2%)	45 (5.5%)	12 (3.3%)	15 (4.3%)	0 (0%)	1 (0.7%)
<b>WHO-2009</b>								
<b>DWoWS</b>	96 (35%)	83 (33%)	70 (42%)	108 (13%)	70 (19%)	71 (20%)	14 (54%)	68 (50%)
<b>DWWS</b>	140 (52%)	122 (48%)	84 (50%)	603 (73%)	201 (55%)	180 (52%)	12 (46%)	61 (45%)
<b>SD</b>	35 (13%)	49 (19%)	15 (8.3%)	110 (13%)	97 (26%)	96 (28%)	0 (0%)	7 (5.1%)

432

433

434

435

436

437 **Table 4. Compensated shock and hypotensive shock by DENV serotype.**

Serotype	Only compensated shock	Only hypotensive shock	Hypotensive from compensated shock
<b>DENV1</b>	52 (62%)	20 (24%)	12 (14%)
<b>DENV2</b>	43 (38%)	30 (26%)	41 (35%)
<b>DENV3</b>	94 (50%)	24 (13%)	69 (37%)

438

439 **Figure Legends**

440

441 **Figure 1. DENV circulation by immune status in the PDCS and PDHS combined, Managua,**

442 **2004-2022.** Circulating serotypes and immune status in Managua are represented. The

443 hospital study was not run in 2020 and 2021.

444

445 **Figure 2. Distribution by immune response among severe dengue cases, PDCS and PDHS**

446 **combined, Managua, 2004-2022.**

447

448 **Figure 3. Model derived severity by DENV serotype of infection and immune status in the**

449 **PDCS and PDHS combined, Managua, 2004-2022.** Model is adjusted by age and sex. Model-

450 derived estimates compared to DENV1 stratified by WHO disease severity classification and

451 immune status, as indicated. Due to sample size, DENV-4 was excluded from the analysis. Blue

452 dotted line, DENV1 reference value. IR, immune response.

453

454 **Figure 4. Clinical signs, clinical lab results, and case management of dengue severity by**

455 **serotype in both primary and secondary cases in the PDCS and PDHS combined, Managua,**

456 **2004-2022.** Mucosal bleeding: epitaxis, gingivorrhagia, conjunctival bleeding, hematuria,

457 hematemesis, melena, vaginal bleeding. ICU, intensive care unit.

458

459 **Figure 5. Symptoms of dengue by serotype in both primary and secondary cases in the PDCS**


460 **and PDHS combined, Managua, 2004-2022.**

461




462 **Figure 1**

463




465 **Figure 2**

466



467


468 **Figure 3**



469

470 **Figure 4**

471




472

473

474 **Figure 5**

475



476